Ryan & Maniskas, LLP announces that a class action lawsuit has been filed in the United States District Court for the District of Arizona on behalf of purchasers of the common stock of Insys Therapeutics Inc (NASDAQ:INSY) between May 1, 2013 and May 8, 2014, inclusive (the “Class Period”). Insys Therapeutics Inc (NASDAQ:INSY) net profit margin is 40.60% and weekly performance is -27.02%. On last trading day company shares ended up $23.85. Analysts mean target price for the company is $62.00. Insys Therapeutics Inc (NASDAQ:INSY) distance from 50-day simple moving average (SMA50) is -41.27%.
22nd Century Group Inc (NYSEMKT:XXII) announced the appointment of Thomas L. James, Esq. as Vice President, General Counsel and Secretary, effective May 12, 2014. 22nd Century Group Inc (NYSEMKT:XXII) shares advanced 6.76% in last trading session and ended the day on $3.00. XXII return on assets is -468.20%. 22nd Century Group Inc (NYSEMKT:XXII) quarterly performance is -3.23%.
On May 6, 2014 , Cytokinetics, Inc. (NASDAQ:CYTK) reported total revenues of $8.0 million for the first quarter of 2014, compared to $0.8 million during the same period in 2013. Net loss for the first quarter of 2014 was $8.7 million or $0.27 per basic share and diluted share. This is compared to a net loss for the same period in 2013, of $12.6 million, or $0.53 per basic and diluted share. As of March 31, 2014, cash, cash equivalents and investments totaled $101.9 million. Cytokinetics, Inc. (NASDAQ:CYTK) shares moved down -0.42% in last trading session and was closed at $4.69, while trading in range of $4.56 – $4.73. Cytokinetics, Inc. (NASDAQ:CYTK) year to date (YTD) performance is -27.85%.
On May 6, 2014 ,Oragenics Inc (NYSEMKT:OGEN) announced that through its Exclusive Channel Collaboration (ECC) with Intrexon Corporation (XON), a leader in synthetic biology, it has produced and analyzed a large number of new potential analogs generated from its Mutacin 1140 (MU1140) lantibiotic program platform, and advanced several promising compounds for further evaluation. These compounds will serve as the basis for selecting a lead drug candidate for clinical development later this year. The triaged analogs were selected from hundreds of variants generated using genetic engineering at Intrexon. Oragenics Inc (NYSEMKT:OGEN) ended the last trading day at $2.00. Company weekly volatility is calculated as 12.51% and price to cash ratio as 4.43. Oragenics Inc (NYSEMKT:OGEN) showed a positive weekly performance of 7.53%.
Leave a Reply